User:Confalone

Pat N. Confalone, Ph. D.

A graduate of M.I.T., Class of 1967, Dr. Confalone obtained a Ph.D. at Harvard in 1970, working for Nobel laureate Prof. R.B. Woodward. Following a post-doctoral stint at Harvard, also under Woodward [The Total Synthesis of Vitamin B12 Project], he joined the Chemical Research Department of Hoffmann-La Roche. After 10 years, he moved to Dupont’s Central Research Department, Life Sciences Division, where his Bioorganic Chemistry group developed the fluorescent dye-labeled reagents that were used in automated DNA sequencing, eventually employed in the human genome project. Dr. Confalone recruited a world class Medicinal Chemistry department which discovered CozaarTM, a major anti-hypertensive based on angiotensin II antagonism. After 21 years in Discovery Research, he moved into pre-clinical development. As Senior Vice-president, he built a highly successful Chemical Process R&D organization which carried out the chemical development of CozaarTM and SustivaTM, a highly successful NNRTI used to treat AIDS. He moved to Bristol-Myers Squibb in 2001 and in 2003 became Vice President , R&D, for Adaptive Therapeutics in La Jolla. Currently, Dr. Confalone is Vice President, Global R&D, in Dupont’s Health, Nutrition, and Ag Sciences platform. Dr. Confalone has presented >120 invited or plenary lectures worldwide, published >140 papers and obtained >60 U.S. and Foreign Patents. He has received numerous honors and awards, including the Alpha Chi Sigma Award, the Harvard Graduate Society Prize, and has been nominated to the Harvard Society of Fellows. Dr. Confalone was Chairman of Natural Products Gordon Conference, and appointed to Editorial Advisory Boards of Current Drugs, Bioorganic and Medicinal Chemistry, The Journal of Organic Chemistry, Synlett, Progress in Heterocyclic Chemistry, Synthesis, Medicinal Chemistry Research, and Drug Design and Discovery. He was elected chair of the Organic Division of the ACS and chair of the ACS Committee on Chemistry and Public Affairs. In 2001 he was elected a Fellow of the American Association for the Advancement of Science.